Lide Pharmaceuticals

LIDE Biotech is a premier Contract Research Organization (CRO) specializing in precision medicine and translational oncology services. The company is widely recognized for its proprietary Mini-PDX technology, a rapid in vivo drug sensitivity assay that provides results within 7 days to guide clinical treatment decisions and drug discovery. LIDE maintains an extensive library of over 2,000 Patient-Derived Xenograft (PDX) models across various cancer types, supporting pharmaceutical partners in efficacy testing and biomarker discovery. Beyond its CRO services, the company operates functional diagnostic platforms that integrate genomic data with real-time drug response profiles to personalize cancer therapy. LIDE Biotech serves a global clientele from its headquarters in Shanghai and its international operations, bridging the gap between laboratory research and clinical application.